<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01197066</url>
  </required_header>
  <id_info>
    <org_study_id>101-KOA-0802i</org_study_id>
    <nct_id>NCT01197066</nct_id>
  </id_info>
  <brief_title>Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Phase Ⅲ Multicenter, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Certolizumab Pegol as Additional Medication to Methotrexate, in Patients With Active Rheumatoid Arthritis Who Participated in Study 101-KOA-0801i</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ⅲ multicenter, open-label, follow-up study, to assess the safety and efficacy
      of certolizumab pegol (CZP) as additional medication to methotrexate (MTX), in patients with
      active rheumatoid arthritis (RA) who participated in Study (Protocol) # 101-KOA-0801i.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety of CZP for a long term period as additional medication to MTX, in patients with active RA, as measured by adverse events frequency, severity and nature; PE and vitals; and laboratory values, blood parameters and urine parameters.</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Treatment will continue until the drug is commercially available in the country.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the clinical response rate measured by ACR20, ACR50 and ACR70 responder rate.</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Treatment will continue until the drug is commercially available in the country.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in patient's Health-Related Quality of Life (HRQOL) as measured by the 36-item Short Form Health Survey (SF-36)</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Treatment will continue until the drug is commercially available in the country.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the achievement of clinical remission measured by DAS28.</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Treatment will continue until the drug is commercially available in the country.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The improvement in physical function as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI).</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Treatment will continue until the drug is commercially available in the country.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Certolizumab Pegol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certolizumab Pegol</intervention_name>
    <description>Certolizumab Pegol 200mg</description>
    <arm_group_label>Certolizumab Pegol</arm_group_label>
    <other_name>CDP870</other_name>
    <other_name>CIMZIA</other_name>
    <other_name>Perstymab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Failed to achieve an ACR20 response at Week 12 in the Study 101-KOA-0801i or completed
             the entire Study 101-KOA-0801i through Week 24

          -  Have a clear chest X-ray at the Entry visit

          -  Negative urine pregnancy test at the Entry

          -  Continue treatment on methotrexate

        Exclusion Criteria:

          -  Any other inflammatory arthritis (e.g., psoriatic arthritis, ankylosing spondylitis or
             reactive arthritis)

          -  Secondary, non-inflammatory type of arthritis (eg, osteoarthritis, fibromyalgia)

          -  At study entry taking any of the prohibited medications as detailed in the Study
             (Protocol) # 101-KOA-0801i

          -  NYHA (New York Heart Association) Class III or IV congestive heart failure

          -  Current or history of tuberculosis

          -  History of chronic infection, recent serious or life-threatening infection or any
             current sign or symptom that may indicate an infection (e.g., fever, cough)

          -  History of a lymphoproliferative disorder including lymphoma or signs and symptoms
             suggesting lymphoproliferative disease

          -  High risk of infection

          -  Female breast feeding, pregnant or plan to become pregnant during the trial or for 12
             weeks following the last dose of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YoungMo Kang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

